Propranolol as an alternative treatment option for pediatric lymphatic malformation.
Tohoku J Exp Med
; 229(1): 61-6, 2013 01.
Article
em En
| MEDLINE
| ID: mdl-23257321
ABSTRACT
Lymphatic malformation (LM), which was previously termed lymphangioma, is a rare congenital malformation of the lymphatic system and its treatment is still challenging. Propranolol (beta blocker) has been recently developed as a first-line treatment of infantile hemangioma. Our study aimed to assess the effect of propranolol on pediatric LM and the relationship between its effectiveness and vascular endothelial growth factor (VEGF) family members (VEGF-A, C and D). Six Japanese patients with LM (age range 10 months-19 years old; 2 macrocystic, 2 microcystic and 2 combined type) were enrolled. Oral propranolol was administered at 2 mg/kg/day. The efficacy of propranolol for LM was evaluated by the rate of volume change as calculated from MRI imaging and by symptomatic improvement. In all patients, there were no significant side effects. Patients 3 and 5 were classified as objective responders with tumor volume reduction of 30.6% and 22.9%, respectively, at 24 weeks. Patient 1 showed 8% tumor volume reduction and patient 6 showed symptomatic improvement, hence, both were classified as minimal responders. The other two patients were classified as non-responders. Plasma VEGF-A, C, and D levels were significantly higher in the LM group than in the controls (all P < 0.01 by Mann-Whitney test). VEGF-A and D levels at 24 weeks were significantly lower than those at pre-treatment (P = 0.031, 0.047 by Wilcoxon matched pairs test). Though further trials with this treatment must be carried out, we propose that propranolol may be an alternative therapy option for intractable LM.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Propranolol
/
Fatores de Crescimento do Endotélio Vascular
/
Linfangioma
Limite:
Humans
/
Infant
País/Região como assunto:
Asia
Idioma:
En
Revista:
Tohoku J Exp Med
Ano de publicação:
2013
Tipo de documento:
Article
País de afiliação:
Japão